Polymorphism, Genetic Clinical Trial
— BDNFOfficial title:
The Effect of BDNF on Motor Learning
Verified date | May 2017 |
Source | University of Minnesota - Clinical and Translational Science Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of the study is to assess the status of brain-derived neurotrophic factor brain
(BDNF) and how the brain behaves in response to skill acquisition. Specifically we will
investigate the relationship of the status of BDNF with cortical excitability changes and
learning that occur during a motor training paradigm. We aim to 1) determine cortical
excitability changes by using transcranial magnetic stimulation (TMS) before and after
training; 2) to determine finger tracking accuracy before and after training; and 3)
determine the presence of BDNF polymorphism in each participant.
We are testing healthy adults in this study, and eventually would like to apply to persons
who have neurologic disorders such as stroke or dystonia. By applying a magnetic field to
the outside of the head, electrical currents are produced within the brain that can
stimulate brain tissue. Using TMS, the brain can be studied to gain a greater understanding
of the mechanisms associated with cortical excitability in healthy and patient populations.
There is limited knowledge of what influence genetic biomarkers such as BDNF have on
cortical excitability changes within the cortex following learning. Studies have indicated
that people without this certain gene are less likely to show changes in brain excitability
during TMS and during motor learning than people with this gene
Status | Terminated |
Enrollment | 24 |
Est. completion date | May 2014 |
Est. primary completion date | May 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - 18-45 years - no past history of psychiatric or neurologic disease. Exclusion Criteria: - any neuromuscular disorder that impairs upper extremity motion or seizure history - Pregnancy - Indwelling metal or medical device that are incompatible with TMS testing. |
Country | Name | City | State |
---|---|---|---|
United States | University of Minnesota | Minneapolis | Minnesota |
Lead Sponsor | Collaborator |
---|---|
University of Minnesota - Clinical and Translational Science Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | BDNF genetic status | BDNF genetic variant screening will be conducted via saliva sample collected at the end of the session on day 1. We will screen for the Val66met polymorphism. | Day 1 | |
Primary | Accuracy Index | A computer quantified tracking performance measure in each test. This is a calculation of accuracy by using the equation: AI = 100(P-E)/P. Where E is the root mean square (r.m.s.) error between the target line and the response line, and P is the size of the individual's target pattern, calculated as the r.m.s. difference between the sine wave and the midline separating the upper and lower phases of the sine wave. The magnitude of P is determined by the scale of the vertical axis, which is the subject's range of finger motion. Therefore, the AI is normalized to each subject's own range of motion and takes into account any differences between subjects in the excursion of the tracking target. The maximum possible score is 100%. Negative scores occur when the response line is so distant from the target that it falls on the opposite side of the midline. | Day 1: posttest after training | |
Secondary | Cortical Excitability | Cortical excitability will be measured with transcranial magnetic stimulation (TMS) single and paired pulse stimulation to measure short-interval intracortical inhibition (SICI), cortical silent period (CSP) and motor evoked potential (MEP) amplitude. | Day 1: baseline | |
Secondary | Cortical Excitability | Cortical excitability will be measured with transcranial magnetic stimulation (TMS) single and paired pulse stimulation to measure short-interval intracortical inhibition (SICI), cortical silent period (CSP) and motor evoked potential (MEP) amplitude. | Day 1: posttest |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01977313 -
Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women
|
N/A | |
Not yet recruiting |
NCT06120543 -
CYP1A2, ABCB1, CYP2C9 and Plasma Concentration of Agomelatine in Adult Patients With Depression
|
||
Completed |
NCT01187173 -
The Fibrosis-Lymphedema Continuum in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT03033810 -
FFR Versus iFR in Assessment of Hemodynamic Lesion Significance
|
N/A | |
Completed |
NCT03627780 -
Genetic Polymorphism and Post Operative Nausea and Vomiting (PONV)
|
||
Recruiting |
NCT00155103 -
Effect of Polymorphisms in the IL-1 Gene Complex on the Development of Chronic Hepatitis and Hepatocellular Carcinoma
|
N/A |